CDXS
Codexis, Inc.·Healthcare
2.24
6.667%(−0.16)
Market ClosedLast Updated: — ET
52W L: $0.9652W H: $3.87
CDXS NEWS
seekingalpha.com
Mar 12
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform
Codexis, Inc. delivered strong FY25 results, with revenue up 19% to $70.4M, driven by a $37.8M technology transfer agreement with Merck. CDXS's ECO Synthesis platform targets the expanding siRNA/RNA therapeutics market, offering scalable, high-margin enzymatic manufacturing as a disruptive alternative to chemical synthesis. Operational improvements included gross margin expansion to 64%, narrowed net loss, and SG&A expense reductions, positioning CDXS for financial sustainability.
feeds.benzinga.com
Mar 12
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours?
Codexis shares jumped 37.8% in after-hours trading after the company reported a profitable fourth quarter and full-year 2025 revenue growth.
seekingalpha.com
Mar 11
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
zacks.com
Mar 11
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
Codexis (CDXS) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.13 per share a year ago.
globenewswire.com
Mar 11
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update.
defenseworld.net
Mar 9
Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing at TD Cowen Conf
Codexis (NASDAQ: CDXS) President and CEO Alison Moore outlined the company's strategic focus on RNA medicines manufacturing at TD Cowen's 46th Annual Health Care Conference, emphasizing expected inflection points in 2026 tied to its ECO Synthesis platform and continued execution in its legacy pharma biocatalysis business. Shift in emphasis toward RNA medicines manufacturing Moore described Codexis
